[HTML][HTML] Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: a randomized clinical trial

AS Chiou, S Choi, M Barriga, Y Dutt-Singkh… - Journal of the American …, 2020 - Elsevier
Background Chronic pruritus causes major morbidity in epidermolysis bullosa (EB). The
substance P-neurokinin 1 receptor (SP-NK1) pathway is a promising target for treating EB-
related pruritus. Objective To evaluate the safety and efficacy of the oral NK1 receptor
antagonist serlopitant in treating moderate-severe pruritus in EB. Methods The study
randomized 14 patients to serlopitant or placebo for 8 weeks, followed by a 4-week washout
and optional open-label extension. The primary end point was change in itch as measured …